Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Morphine is **not a target molecule or receptor**; it is a small-molecule drug classified as a natural opium alkaloid and the principal active compound of opium[1][3][5][9]. Morphine acts pharmacologically as a classic opioid analgesic by binding to and activating opioid receptors—primarily the mu-opioid receptor—in the central and peripheral nervous systems to block pain transmission[2][6][7]. It is used to manage moderate to severe pain and has been foundational in the development of both opioid receptor pharmacology and analgesic drug development. As such, morphine is a **ligand (drug)**, not a therapeutic target (such as a receptor, enzyme, or transporter) and should not be catalogued as a drug target[2][3][7].\n\n**Note:**\n- If you are seeking information about morphine's primary therapeutic target, it is the **mu-opioid receptor** (sometimes abbreviated as MOR or OPRM1), which is a G protein-coupled receptor involved in pain modulation and other physiological processes[2][6][7].\n- For structured information, please use the **mu-opioid receptor** as the canonical therapeutic target in drug-target databases.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Morphine.